{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-081052","form_type":"8-K","ticker":"NEUP","cik":"0001191070","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2026-07-23T22:37:29+00:00","discovered_at":"2026-07-24T10:05:00.240748+00:00","generated_at":"2026-07-24T10:05:53.612712+00:00","sec_items":["1.01","5.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Neuphoria Therapeutics to be acquired by Scancell Holdings in all-stock merger with CVRs","bullets":["Neuphoria shareholders to receive Parent ADSs and contingent value rights; expected to own ~11.1% of combined company.","Scancell shareholders to own ~64.9%; PIPE investors to own ~17.3% with $38.6M gross proceeds at $0.1205/ADS.","Closing conditions include stockholder approvals, Nasdaq listing of Parent ADSs, and at least $75M in PIPE proceeds.","CVRs entitle holders to 100% of net proceeds from Merck collaboration, Pfizer/KAT6 license, and R&D tax credit over 15 years.","UK Placing of ~$12M and Retail Offer up to $3M also announced; not conditional on merger completion."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-081052","json":"https://secwatch.observer/filing/0001213900-26-081052.json","markdown":"https://secwatch.observer/filing/0001213900-26-081052.md","text":"https://secwatch.observer/filing/0001213900-26-081052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1191070/000121390026081052/0001213900-26-081052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1191070/000121390026081052/ea0298914-8k_neuphoria.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-24T10:05:53.612712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}